Filing Flows › NovoCure (NVCR) › Guidance & outlook
NovoCure (NVCR) guidance and outlook
NovoCure (NVCR) raised its guidance on Oct 29, 2026: Revenue $736M–$743M for FY2026; EBITDA $24.0M–$34.0M for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $736M–$743M | raised |
| EBITDA | FY2026 | $24.0M–$34.0M | raised |
| Revenue | FY2026 | $30.0M–$34.0M | new |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
NovoCure's latest quarter
NovoCure, Q3 2026: revenue $193M (+16% year over year), operating margin -3.2%, net loss $10.4M, operating cash flow $22.7M. The chart follows the revenue to costs, profit and cash.
Questions
Did NovoCure raise or lower its guidance?
NovoCure (NVCR) raised its guidance on Oct 29, 2026: Revenue $736M–$743M for FY2026; EBITDA $24.0M–$34.0M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.